Prostate cancer is one of the rampant diseases found in middle aged men and old men. There are many drugs used to treat the disease but one of the most effective is acetate. Recently, Glenmark Pharma got the approval for Abiraterone Acetate tablets USP, 250 mg which is used to treat prostate cancer. Glenmark Pharmaceuticals Inc.., USA finally received the approval by the United States Food & Drug Administration to sell the drug for prostate cancer.
The current portfolio of Glenmark Pharmaceuticals consists of 162 products, which are authorised for distribution in the US marketplace. And it also has 46 ANDA’s pending approval with the USFDA.
Zytiga Tablets is the best form of medicines of the acetate tablets. Moreover, the generic version of acetate tablets is Zytiga Tablets designed by Glenmark Pharmaceuticals specifically Janssen Biotech created. And the approximate annual sales of the Zytiga tablets, 250 mg market was $794.1 million by the 12 month ending period of August 2019. It’s a healthy growth and Glenmark Pharmaceuticals wants to invest more on a market that’s growing.
Prostate cancer is a common disease and Zytiga Tablets are the common type of medicine that is doctor advised. Glenmark Pharmaceuticals got the approval for its own version of acetate tablets. It is doing good as a business now with its shares closing at 0.75 per cent higher at Rs 288 apiece on the BSE.
Hopefully its USFDA approved product does well in the long run.